Amerikanische Gesellschaft für Hirudotherapie

Two heads are better than one: crystal structure of the insect derived double domain Kazal inhibitor rhodniin in complex with thrombin

Research article published in The EMBO journal (1995)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Arzneimittelentwicklungvan de Locht A et al. · The EMBO journal, 1995

Abstract

Rhodniin is a highly specific inhibitor of thrombin isolated from the assassin bug Rhodnius prolixus. The 2.6 Angstrum crystal structure of the non-covalent complex between recombinant rhodniin and bovine alpha-thrombin reveals that the two Kazal-type domains of rhodniin bind to different sites of thrombin. The amino-terminal domain binds in a substrate-like manner to the narrow active-site cleft of thrombin; the imidazole group of the P1 His residue extends into the S1 pocket to form favourable hydrogen/ionic bonds with Asp189 at its bottom, and additionally with Glu192 at its entrance. The carboxy-terminal domain, whose distorted reactive-site loop cannot adopt the canonical conformation, docks to the fibrinogen recognition exosite via extensive electrostatic interactions. The rather acidic polypeptide linking the two domains is displaced from the thrombin surface, with none of its residues involved in direct salt bridges with thrombin. The tight (Ki = 2 x 10(-13) M) binding of rhodniin to thrombin is the result of the sum of steric and charge complementarity of the amino-terminal domain towards the active-site cleft, and of the electrostatic interactions between the carboxy-terminal domain and the exosite.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAmino Acid SequenceAnimalsBinding SitesCattleCrystallizationHirudinsInsect HormonesInsect ProteinsMolecular Sequence DataProtein ConformationRhodniusSequence Alignment

Zusammenfassung

Rhodniin is a highly specific inhibitor of thrombin isolated from the assassin bug Rhodnius prolixus.

Warum dies für die Hirudotherapie relevant ist

This article reports the 2.6 Å crystal structure of rhodniin, a highly specific thrombin inhibitor from the assassin bug Rhodnius prolixus, in complex with bovine alpha-thrombin. The abstract describes a two-Kazal-domain inhibitor whose N-terminal domain binds the active site in substrate-like fashion (P1 His in the S1 pocket) while the C-terminal domain docks the fibrinogen recognition exosite, yielding tight binding (Ki ~2 x 10^-13 M). For ASH, this is relevant as a comparative example of convergent dual-site thrombin inhibition in a blood-feeding arthropod, conceptually paralleling hirudin's mechanism. The caveat is that no leeches or leech-derived molecules are involved; relevance is indirect and comparative only.

Zitation

Two heads are better than one: crystal structure of the insect derived double domain Kazal inhibitor rhodniin in complex with thrombin

van de Locht A et al. · The EMBO journal, 1995

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.